Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
While much of the attention in animal health focuses on consumer-facing products and biotech breakthroughs, a quieter but equally impactful segment is expanding rapidly: veterinary Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs). These business-to-business (B2B) partners are now essential enablers of innovation, helping veterinary pharmaceutical companies bring new products from molecule to market.
According to new figures from Towards Healthcare, the global market for veterinary CROs and CDMOs is valued at $7.17 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.4% through 2034. While North America currently leads in revenue, the Asia-Pacific region is experiencing the fastest growth—driven by cost-efficiency, government research support, and expanding biotech capabilities.
The most in-demand services include biologics development, oral drug formulation, and Good Manufacturing Practice (GMP)-compliant production, particularly for companion animals, with dogs being the leading species of focus. At the same time, there is increasing interest in aquaculture and livestock applications, as producers seek outsourced capabilities to scale new therapeutics in protein-intensive sectors.
This shift toward externalized research and development (R&D), as well as outsourced manufacturing, isn’t just tactical—it’s highly strategic. Emerging animal health startups are using veterinary CROs and CDMOs to reduce internal overhead and scale flexibly with minimal capital expenditure. Meanwhile, established players are leveraging these partners to accelerate time-to-market, improve cost predictability, and reduce risk as they diversify their R&D pipelines.
Mergers and acquisitions (M&A) in the CRO/CDMO space are also on the rise. Full-service organizations offering integrated regulatory affairs, clinical trials, formulation development, and manufacturing under one roof are commanding premium valuations. Many are now incorporating artificial intelligence (AI) into protocol design and trial monitoring systems—further speeding up development cycles while reducing failure rates.
In essence, contract research and manufacturing partners are becoming the invisible backbone of veterinary innovation. Their impact spans from startup drug development to global vaccine production, and they are crucial in meeting the rising demand for safe, scalable, and compliant animal health solutions.
For investors, the appeal is strong: a market with high outsourcing propensity, long-term B2B service contracts, and growing alignment with the broader veterinary biotech boom. These “quiet giants” may not be front and center—but they are powering the next generation of breakthroughs in animal health.
All rights reserved to The Animal Economics © Copyright 2026 | Web design & implementation: PAQ Consultancy
This website uses cookies. For details, please see our privacy policy. By clicking on the relevant button or any other element of the page, you consent to the use of cookies.